Impact of breakthrough therapy designation on cancer drug development
Gespeichert in:
| Veröffentlicht in: | Nature reviews. Drug discovery 2016-03, Vol.15 (3), p.152-152 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 152 |
|---|---|
| container_issue | 3 |
| container_start_page | 152 |
| container_title | Nature reviews. Drug discovery |
| container_volume | 15 |
| creator | Shea, Michael Ostermann, Linda Hohman, Ryan Roberts, Samantha Kozak, Marina Dull, Ryan Allen, Jeff Sigal, Ellen |
| description | |
| doi_str_mv | 10.1038/nrd.2016.19 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_cross</sourceid><recordid>TN_cdi_gale_infotracmisc_A447930835</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A447930835</galeid><sourcerecordid>A447930835</sourcerecordid><originalsourceid>FETCH-LOGICAL-c304t-d2a2e4962b602736cf748338bcf70e5f1a4b1fa6007de5217031476789c4f32f3</originalsourceid><addsrcrecordid>eNptkN9LwzAQx4MoOKdP_gMFH7U1v9a0j2NMHQx80eeQppcuc01K0gn7782YCMK4gzvuPnfcfRG6J7ggmFXPLrQFxaQsSH2BJoQLnhNR8cu_XJTX6CbGLU4QEXSClqt-UHrMvMmaAOpr3AS_7zbZuIGghkPWQrSdU6P1LkuuldMQsjbsu9T6hp0fenDjLboyahfh7jdO0efL8mPxlq_fX1eL-TrXDPMxb6miwOuSNiWmgpXaCF4xVjUpwTAzRPGGGFViLFqYUSIwS3eXoqo1N4waNkUPp72d2oG0zvgxKN3bqOWcc1EzXLFZooozVLIWequ9A2NT_d_A42lABx9jACOHYHsVDpJgeRRWJmHlUVhJ6kQ_neiYKNdBkFu_Dy79fRb_AQh4eNE</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Impact of breakthrough therapy designation on cancer drug development</title><source>Nature</source><source>Alma/SFX Local Collection</source><creator>Shea, Michael ; Ostermann, Linda ; Hohman, Ryan ; Roberts, Samantha ; Kozak, Marina ; Dull, Ryan ; Allen, Jeff ; Sigal, Ellen</creator><creatorcontrib>Shea, Michael ; Ostermann, Linda ; Hohman, Ryan ; Roberts, Samantha ; Kozak, Marina ; Dull, Ryan ; Allen, Jeff ; Sigal, Ellen</creatorcontrib><identifier>ISSN: 1474-1776</identifier><identifier>EISSN: 1474-1784</identifier><identifier>DOI: 10.1038/nrd.2016.19</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>631/154/109 ; 631/154/155 ; 692/699/67/1059/153 ; Antineoplastic agents ; biobusiness-briefs ; Biomedicine ; Biotechnology ; Cancer Research ; Drug approval ; Forecasts and trends ; Market share ; Medicinal Chemistry ; Molecular Medicine ; Pharmaceutical industry ; Pharmacology/Toxicology ; Product development</subject><ispartof>Nature reviews. Drug discovery, 2016-03, Vol.15 (3), p.152-152</ispartof><rights>Springer Nature Limited 2016</rights><rights>COPYRIGHT 2016 Nature Publishing Group</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c304t-d2a2e4962b602736cf748338bcf70e5f1a4b1fa6007de5217031476789c4f32f3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids></links><search><creatorcontrib>Shea, Michael</creatorcontrib><creatorcontrib>Ostermann, Linda</creatorcontrib><creatorcontrib>Hohman, Ryan</creatorcontrib><creatorcontrib>Roberts, Samantha</creatorcontrib><creatorcontrib>Kozak, Marina</creatorcontrib><creatorcontrib>Dull, Ryan</creatorcontrib><creatorcontrib>Allen, Jeff</creatorcontrib><creatorcontrib>Sigal, Ellen</creatorcontrib><title>Impact of breakthrough therapy designation on cancer drug development</title><title>Nature reviews. Drug discovery</title><addtitle>Nat Rev Drug Discov</addtitle><subject>631/154/109</subject><subject>631/154/155</subject><subject>692/699/67/1059/153</subject><subject>Antineoplastic agents</subject><subject>biobusiness-briefs</subject><subject>Biomedicine</subject><subject>Biotechnology</subject><subject>Cancer Research</subject><subject>Drug approval</subject><subject>Forecasts and trends</subject><subject>Market share</subject><subject>Medicinal Chemistry</subject><subject>Molecular Medicine</subject><subject>Pharmaceutical industry</subject><subject>Pharmacology/Toxicology</subject><subject>Product development</subject><issn>1474-1776</issn><issn>1474-1784</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><recordid>eNptkN9LwzAQx4MoOKdP_gMFH7U1v9a0j2NMHQx80eeQppcuc01K0gn7782YCMK4gzvuPnfcfRG6J7ggmFXPLrQFxaQsSH2BJoQLnhNR8cu_XJTX6CbGLU4QEXSClqt-UHrMvMmaAOpr3AS_7zbZuIGghkPWQrSdU6P1LkuuldMQsjbsu9T6hp0fenDjLboyahfh7jdO0efL8mPxlq_fX1eL-TrXDPMxb6miwOuSNiWmgpXaCF4xVjUpwTAzRPGGGFViLFqYUSIwS3eXoqo1N4waNkUPp72d2oG0zvgxKN3bqOWcc1EzXLFZooozVLIWequ9A2NT_d_A42lABx9jACOHYHsVDpJgeRRWJmHlUVhJ6kQ_neiYKNdBkFu_Dy79fRb_AQh4eNE</recordid><startdate>20160301</startdate><enddate>20160301</enddate><creator>Shea, Michael</creator><creator>Ostermann, Linda</creator><creator>Hohman, Ryan</creator><creator>Roberts, Samantha</creator><creator>Kozak, Marina</creator><creator>Dull, Ryan</creator><creator>Allen, Jeff</creator><creator>Sigal, Ellen</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20160301</creationdate><title>Impact of breakthrough therapy designation on cancer drug development</title><author>Shea, Michael ; Ostermann, Linda ; Hohman, Ryan ; Roberts, Samantha ; Kozak, Marina ; Dull, Ryan ; Allen, Jeff ; Sigal, Ellen</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c304t-d2a2e4962b602736cf748338bcf70e5f1a4b1fa6007de5217031476789c4f32f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>631/154/109</topic><topic>631/154/155</topic><topic>692/699/67/1059/153</topic><topic>Antineoplastic agents</topic><topic>biobusiness-briefs</topic><topic>Biomedicine</topic><topic>Biotechnology</topic><topic>Cancer Research</topic><topic>Drug approval</topic><topic>Forecasts and trends</topic><topic>Market share</topic><topic>Medicinal Chemistry</topic><topic>Molecular Medicine</topic><topic>Pharmaceutical industry</topic><topic>Pharmacology/Toxicology</topic><topic>Product development</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Shea, Michael</creatorcontrib><creatorcontrib>Ostermann, Linda</creatorcontrib><creatorcontrib>Hohman, Ryan</creatorcontrib><creatorcontrib>Roberts, Samantha</creatorcontrib><creatorcontrib>Kozak, Marina</creatorcontrib><creatorcontrib>Dull, Ryan</creatorcontrib><creatorcontrib>Allen, Jeff</creatorcontrib><creatorcontrib>Sigal, Ellen</creatorcontrib><collection>CrossRef</collection><jtitle>Nature reviews. Drug discovery</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Shea, Michael</au><au>Ostermann, Linda</au><au>Hohman, Ryan</au><au>Roberts, Samantha</au><au>Kozak, Marina</au><au>Dull, Ryan</au><au>Allen, Jeff</au><au>Sigal, Ellen</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Impact of breakthrough therapy designation on cancer drug development</atitle><jtitle>Nature reviews. Drug discovery</jtitle><stitle>Nat Rev Drug Discov</stitle><date>2016-03-01</date><risdate>2016</risdate><volume>15</volume><issue>3</issue><spage>152</spage><epage>152</epage><pages>152-152</pages><issn>1474-1776</issn><eissn>1474-1784</eissn><cop>London</cop><pub>Nature Publishing Group UK</pub><doi>10.1038/nrd.2016.19</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1474-1776 |
| ispartof | Nature reviews. Drug discovery, 2016-03, Vol.15 (3), p.152-152 |
| issn | 1474-1776 1474-1784 |
| language | eng |
| recordid | cdi_gale_infotracmisc_A447930835 |
| source | Nature; Alma/SFX Local Collection |
| subjects | 631/154/109 631/154/155 692/699/67/1059/153 Antineoplastic agents biobusiness-briefs Biomedicine Biotechnology Cancer Research Drug approval Forecasts and trends Market share Medicinal Chemistry Molecular Medicine Pharmaceutical industry Pharmacology/Toxicology Product development |
| title | Impact of breakthrough therapy designation on cancer drug development |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-18T16%3A03%3A47IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Impact%20of%20breakthrough%20therapy%20designation%20on%20cancer%20drug%20development&rft.jtitle=Nature%20reviews.%20Drug%20discovery&rft.au=Shea,%20Michael&rft.date=2016-03-01&rft.volume=15&rft.issue=3&rft.spage=152&rft.epage=152&rft.pages=152-152&rft.issn=1474-1776&rft.eissn=1474-1784&rft_id=info:doi/10.1038/nrd.2016.19&rft_dat=%3Cgale_cross%3EA447930835%3C/gale_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rft_galeid=A447930835&rfr_iscdi=true |